Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesLongitudinally Extensive Myelopathy in Caucasians: A West Australian Study of 26 cases from the Perth Demyelinating Diseases Database
Journal of Neurology, Neurosurgery, and Psychiatry , 09/14/09
Qiu W et al. – LEM occurred as part of CMS or NMO or in isolation. Patients with LEM had highly heterogeneous clinical characteristics and a low rate of AQP4–IgG seropositivity.
Related Articles
The Antiapoptotic Activity of Melatonin in Neurodegenerative Diseases
CNS Neuroscience & Therapeutics, 11/11/09
Relevance Score: 68%
Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies
Journal of the Peripheral Nervous System, 11/16/09
Relevance Score: 66%
Impact of multiple sclerosis relapses on progression diminishes with time
Neurology, 11/06/09
Relevance Score: 66%
Ectopic expression of polysialylated neural cell adhesion molecule in adult macaque Schwann cells promotes their migration and remyelination potential in the central nervous system
Brain, 11/03/09
Relevance Score: 66%
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation
Multiple Sclerosis, 11/03/09
Relevance Score: 65%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Micro-ribonucleic acid profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain, 12/04/09
Dysregulated Epstein-Barr virus infection in patients with CIDP
Journal of Neuroimmunology, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor